The Cigna Group (CI)

Environment story

Cigna discloses limited quantitative emissions data. Scope 1 and Scope 2 emissions are not disclosed in provided filings. Scope 3 supply-chain emissions are undisclosed, triggering a 15-point deduction. No explicit net-zero target year is stated; no disclosed net-zero commitment date was found, triggering a 15-point deduction. The 10-K acknowledges climate-change risks (natural disasters, increasing frequency) but does not articulate a credible decarbonization strategy or investments in physical decarbonization infrastructure. No resource controversies (toxic waste, water, habitat) are documented in the provided materials. Greenwashing detection: No evidence of reliance on carbon offsets rather than operational reduction. No disclosure of supply-chain emissions >70% of footprint. Score reflects absence of disclosed climate commitments, missing Scope 3 data, and no stated net-zero target.

Social story

CEO-to-median-worker pay ratio is 310:1 (CEO total compensation $22.87M; median employee $73,674), exceeding the 200:1 threshold and triggering a 15-point deduction. No documented union-suppression activities or major strikes within 24 months are disclosed; no deduction applied. Leadership diversity data shows gender pay equity (female employees earn >99 cents per dollar of male counterparts on a U.S. basis; >99 cents globally). Specific percentages of women and underrepresented groups in executive/board leadership are not quantitatively disclosed in provided materials, but no indication of diversity below 30% threshold. No supply-chain human-rights hazards (cobalt, lithium) are documented; no deduction applied. The company reports diversity commitments, pay-equity monitoring, and leadership development initiatives. Score reflects high CEO-to-worker pay disparity offset by positive pay-equity practices and absence of documented labor disputes.

Governance story

Cigna operates with a single-class share structure (no dual-class voting supermajority), eliminating a 20-point deduction. Board independence is not explicitly quantified in provided materials; proxy states board composition includes independent directors and describes governance practices but does not disclose a specific percentage. Assuming standard large-cap independence practices (likely >75%), no deduction is applied, but this represents a data gap. Lobbying expenditures are not quantified in dollar terms in provided materials; the proxy references 'active, principles-based' lobbying but does not disclose annual spend. No evidence of active lobbying targeting climate-regulation rollbacks or consumer-protection weakening is documented. Significant regulatory proceedings are disclosed: FTC complaint (September 2024) regarding PBM rebate practices, settled in February 2026 without monetary penalty or admission of fault; AI-related litigation (claims of improper use of PxDx algorithm in claims evaluation); HIPAA voluntary audit (2025, no enforcement action). These do not rise to 'active' antitrust/fraud proceedings with material penalties at the time of assessment. Governance practices include clawback policies, anti-hedging/anti-pledging rules, stock ownership requirements, shareholder special-meeting rights (25% threshold), and proxy access. No shareholder rights plan exists. Score reflects strong governance framework, single-class structure, and absence of major active regulatory violations, offset by non-disclosure of board independence percentage.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of The Cigna Group. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open The Cigna Group in the app for interactive charts and portfolio building.

More in Healthcare